stockrow
Friday 6 November 2026
Export COGT’s income statement to Excel — free account
Cogent Biosciences, Inc.
COGT Healthcare Biotechnology
- EPS
- +1.89%
- Free cash flow
- −42.0%
Quarter to June 2026, against a year earlier
31.60
2.02
+6.83%
Follow COGT
Alert me
Cogent Biosciences, Inc. (COGT) P/B ratio
As of 6 November 2026, Cogent Biosciences, Inc. (COGT) trades at a P/B ratio of 11.6×. Over the past ten years it has ranged from 0.0× (December 2020) to 34.4× (September 2025); the current reading is higher than 92% of that period. That is above the Biotechnology industry median of 2.1× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2020 | 1.0× | 45.51% |
| FY2019 | 0.7× | (62.01%) |
| FY2018 | 1.8× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2020 | 0.0× | — |
| Jun 2020 | 0.7× | 53.75% |
| Mar 2020 | 0.5× | (29.99%) |
| Dec 2019 | 0.7× | 79.18% |
| 11 more quarters | Free account |
Against its own ten years
Low 0.0×
High 34.4×
Ten-year median
3.2×
Current reading's percentile
92
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | n/m |
| CRSP CRISPR Therapeutics AG compare | 2.9× |
| DNTH Dianthus Therapeutics, Inc. compare | 4.0× |
| MANE Veradermics Incorporated compare | 6.9× |
| COGT Cogent Biosciences, Inc. | 11.6× |
| ERAS Erasca, Inc. compare | 12.3× |
| SRRK Scholar Rock Holding Corporation compare | 24.2× |
| KOD Kodiak Sciences Inc. compare | 101× |
| TVTX Travere Therapeutics, Inc. compare | 207× |
| Biotechnology industry median | 2.1× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on COGT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement